CDKN1B and cancer: Notably, an increased reliance on CDK2 may be a therapeutic vulnerability, suggesting an opportunity for CDK2 inhibitors in cancers that delete CDKN1B (although, unlike CDK4/6 inhibitors, CDK2 inhibitors have not yet been successful in the clinic due to high toxicity (146)).